New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareP21 vs Semaglutide

P21 vs Semaglutide

Side-by-side comparison of key properties, dosing, and research.

Cognitive EnhancementAnti-Aging & Longevity
P21
GLP-1 / Weight Loss Agonists
Semaglutide
Summary
P21 is a synthetic peptide derived from CNTF (ciliary neurotrophic factor) that promotes hippocampal neurogenesis, enhances memory and spatial learning, and may reduce amyloid-beta pathology. It is used as a neurogenic and cognitive enhancer with potential anti-Alzheimer's applications.
Semaglutide is an FDA-approved GLP-1 receptor agonist originally developed for type 2 diabetes that has proven remarkably effective for weight loss. Clinical trials show average 15–20% body weight reduction. It is marketed as Ozempic (diabetes) and Wegovy (weight management).
Half-Life
Not well characterized; likely short, but neurogenic effects persist long after administration
~7 days
Admin Route
SubQ, Intranasal
SubQ, Oral
Research
Typical Dose
100–500 mcg
0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg
Frequency
Once daily
Once weekly, subcutaneous
Key Benefits
  • Promotes hippocampal neurogenesis
  • Enhances spatial memory and learning
  • Increases BDNF expression
  • Reduces amyloid-beta plaque formation (animal models)
  • Anti-tau pathology potential
  • Cognitive enhancement without stimulant effects
  • Potential therapeutic for Alzheimer's and cognitive aging
  • Average 15–20% body weight reduction in clinical trials (STEP trials)
  • Significant reduction in appetite and food cravings
  • Improvement in blood sugar control and insulin sensitivity
  • Reduces cardiovascular risk (SELECT trial: 20% reduction in MACE)
  • May reduce risk of kidney disease
  • Improves metabolic markers (cholesterol, blood pressure)
  • FDA-approved — extensively studied with robust safety data
  • Weekly dosing convenience
Side Effects
  • Generally well tolerated in animal studies
  • Limited human clinical data
  • Injection site reactions
  • Potential mild fatigue at initiation
  • Nausea (most common, especially during titration)
  • Vomiting
  • Diarrhea or constipation
  • Abdominal discomfort
  • +4 more
Stacks With